Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 9/20 | 0.49 |
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19668485 | 0.79 | SCN4A (0.59) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL19668508 | 0.78 | SCN4A (0.62) | SCN4ATACR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL19686115 | 0.75 | SCN4A (0.48) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL28202257 | 0.75 | SLC22A12 (0.47) | SLC22A12 | |
| SCHEMBL19668700 | 0.72 | CYP11B1 (0.48) | SLC22A12HSD11B1 | |
| SCHEMBL2387153 | 0.72 | SLC22A12 (0.46) | SLC22A12 | |
| SCHEMBL19686114 | 0.71 | SCN4A (0.47) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL18306060 | 0.71 | SCN4A (0.55) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL15021818 | 0.71 | TRPM8 (0.47) | — | |
| SCHEMBL14405542 | 0.71 | TRPM8 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492325-B2 | Compounds as inhibitors of sodium channels | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2022-11-08 | — | — | US | disclosed |
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2017210371-A2 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270696-A1 | COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | SCN1B, CACNA1E, SCN2B | SCN4A 48/4885TACR1 174/4885CACNA1F 18/4885 |
| US-11492325-B2 | Compounds as inhibitors of sodium channels | SCN1B, CACNA1E, SCN2B | SCN4A 48/4885TACR1 174/4885CACNA1F 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.